ArticlePediatric cardiology2026
NT-pro Brain Natriuretic Peptide in Infants with Single Ventricle Heart Disease in the CHAMP® Multi-site Registry.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The role of NT-pro Brain Natriuretic Peptide (NT-proBNP) and BNP in single ventricle (SV) patients during the interstage period is not well understood. We sought to describe NT-proBNP and BNP in a large group of SV infants and to determine if there is an association between pre-discharge NT-proBNP and interstage outcomes (unplanned hospitalizations [UPH]/interventions). We identified SV infants at 11 Cardiac High Acuity Monitoring Program (CHAMP) centers from 2014 to 2021 using the CHAMP multisite registry. Patients with NT-proBNP/BNP drawn prior to neonatal discharge were included, with the last value identified. Demographics, clinical characteristics, and events were collected. zlog transformation was used to convert NT-proBNP values to a normal distribution. Two-sided t-tests (α = 0.05) were used to evaluate average differences in zlog transformed NT-proBNP between patients with an UPH/intervention versus those with neither. 268 patients (male = 178, 66.4%) were included. The most common diagnosis was hypoplastic left heart syndrome, (N = 105, 39.2%). Median NT-proBNP (N = 136) and BNP (N = 132) were 5295 (IQR 2905-8590) and 299 (IQR 158-543), respectively, with median zlog-NT-proBNP 2.87 (IQR 2.24, 3.55). UPH/interventions occurred in 142 patients (53%). There was no significant difference in zlog-NT-proBNP in patients with UPH/interventions versus neither (p-value = 0.872). We described BNP, NT-proBNP, and zlog-NT-proBNP in SV infants at interstage discharge. Further investigation is needed to understand whether NT-proBNP/BNP and zlog-NT-proBNP can prognosticate outcomes after initial SV/interstage discharge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.